title: Management of the axilla.
abstract: The development and wide acceptance of sentinel lymph node biopsy (SLNB) has profoundly affected the management of breast cancer. SLNB has spared the additional morbidity of axillary lymph node dissection (ALND) without compromising diagnostic accuracy and prognostic information in patients with clinically node-negative early-stage breast cancer. It has become an invaluable tool to clinicians to guide decisions regarding adjuvant treatment. The management of breast cancer continues to advance to more minimally invasive approaches, and the role of ALND is likely to become less important in the future.
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Saul and Joyce Brandman Breast Center, Los Angeles, CA 90048, USA.
authors.forename: Farin
authors.initials: F
authors.lastname: Amersi
authors.forename: Armando E
authors.initials: AE
authors.lastname: Giuliano
mesh_terms: D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D000075202:Contraindications; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008408:Mastectomy; D020360:Neoadjuvant Therapy; D021701:Sentinel Lymph Node Biopsy / Q000379:methods
keywords: ACOSOG Z0010; ACOSOG Z0011; Axillary node dissection; Sentinel lymph node biopsy